In a bid to capitalize on the increasing prevalence of cannabis consumption in the US, pharmaceutical companies have introduced a new pill that claims to combat marijuana addiction. The experimental drug, AEF-0117, has shown promise in a small trial by reducing the addictive impact of THC, the primary psychoactive compound in cannabis. While the study published in the journal Nature Medicine may appear encouraging at first glance, a closer examination raises several concerns about the motives behind such pharmaceutical interventions.
High Times sent Ethan Zohn across the country during the World Cup to find where…
When most people think about the FIFA World Cup, they think about moments. The winning…
As younger consumers rethink their relationship with alcohol, retailers like SWADE Cannabis are betting cannabis…
Pepper’s drummer reflects on Point Break Festival, reggae-rock’s traveling family, growing up around Hawaiian cannabis,…
The hearing that could decide weed’s federal future starts June 29. The DEA invited seven…
Robinhood is a popular US-based investment app that allows everyday individuals to buy and sell…